Intra-Cellular Therapies, Inc.
—- Market cap
- —
- Debt
- +$216.05M
- Cash
- −$306.95M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $28.00B · View financials
Decision snapshot: ITCI stock price vs QSR: inconclusive — current versus $18.97 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at QSR's multiple
Implied fair value · at ITCI's multiple
Needs ITCI P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ITCI FY 2024 (ended Dec 31, 2024) · QSR FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 68% equity / 32% debt
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Intra-Cellular Therapies, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
RESTAURANT BRANDS INTERNATIONAL INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.19x
3.66x
Net debt / EBITDA
Leverage against operating earnings
1.23x
—
Cash and equivalents
Liquid reserves on the balance sheet
$306.95M
—
Total debt
Interest-bearing obligations outstanding
$216.05M
$13.31B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ITCI vs SUPN
ACADIA PHARMACEUTICALS INC
ITCI vs ACAD
Vanda Pharmaceuticals Inc.
ITCI vs VNDA
Sage Therapeutics, Inc.
ITCI vs SAGE
MCDONALDS CORP
ITCI vs MCD
YUM BRANDS INC
ITCI vs YUM
CHIPOTLE MEXICAN GRILL INC
ITCI vs CMG
DOMINOS PIZZA INC
ITCI vs DPZ
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.